Key result
EnteroX treatment in cPVR transgenic mice infected with poliovirus type 1 resulted in an approximately 80% higher survival rate and reduced viral titers by 3 to 5 log10 compared to controls.
Population
Cell cultures infected with picornaviruses and cPVR transgenic mice infected with 3 x 10^8 PFU of poliovirus…
Comparison
EnteroX administered once daily by… vs Control animals
Design
Preclinical
Follow-up
5 days postinfection
Authors
Loading...
May support EnteroX development for poliovirus; leaves open human efficacy pending clinical trials.
EnteroX, a PPMO targeting conserved IRES sequences, significantly reduces poliovirus replication in vitro and improves survival while reducing tissue viral load in a transgenic mouse model.
Stone et al. (2008) studied Poliovirus type 1 infection. EnteroX (PPMO targeting IRES sequence) vs. controls was evaluated on Survival rate. EnteroX treatment in cPVR transgenic mice infected with poliovirus type 1 resulted in an approximately 80% higher survival rate and reduced viral titers by 3 to 5 log10 compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: